Dejan Juric
Advertisement
Articles by Dejan Juric
15 Updated Expert Consensus Recommendations for Managing Hyperglycemia and Rash in Patients With PIK3CA-Mutated, Hormone Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2–Negative (HER2–) Advanced Breast Cancer Treated With Alpelisib
ByEmily J. Gallagher,Heather Moore,Mario E. Lacouture, MD,Susan F. Dent,Azeez Farooki, MD,Marcus D. Goncalves,Claudine Isaacs, MD,Abigail Johnston,Dejan Juric,Zoe Quandt,Laura Spring,Brian Berman,Melanie Decker,Gabriel N. Hortobagyi, MD, FACP,Benjamin H. Kaffenberger,Bernice Y. Kwong,Timothy Pluard,Ruta Rao, MD,Lee Schwartzberg, MD, FACP,Michael S. Broder
Advertisement
Latest Updated Articles
![TPS 25 Phase 1/2 Study of the Novel Radioligand Therapy [177Lu]Lu-NeoB Plus Capecitabine in Patients With ER+/HER2− Advanced Breast Cancer (ABC) With GRPR Expression After Progression on Prior Endocrine Therapy Plus a CDK4/6 Inhibitor for ABC](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/bb58c5f3c3692dc35c19320bb63c3df864f9b79b-1500x722.png?w=300&fit=crop&auto=format)
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy
2
Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer
3
FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer
4
FDA Accepts sNDA for Taletrectinib in ROS1-Positive NSCLC
5